Green Cross announced on Feb. 16 that its research paper on action mechanism of “GC1118”, a bio new medical product that has been co-developed with Mogam Biotechnology Research Institute (MBRI), was published in highlights of the latest issue of Molecular Cancer Therapeutics, an international medical journal published by the American Association for Cancer Research (AACR).
GC1118 is a targeted agent that selectively attacks specific factors related to the growth of cancer cells. It inhibits tumour cells by blocking broad spectrum of epidermal growth factor receptor (EGFR) ligand binding, receptor activation and downstream signaling. At the same time, it brings in immune cells and attacks cancel cells with cytotoxicity.
According to the research paper, GC1118 showed broader and better tumour inhibitory efficacy on various EGFR growth factors than existing EGFR-targeted agents in preclinical animal trials due to its differentiated binding force and novel mode of action.
Accordingly, it will have a curative power even in patients, who don’t respond or show clinical resistance to existing anti-EGFR agents, and the effect can last longer.